Mianserine Eg

Mianserin, the active ingredient in Mianserine Eg, is a tetracyclic antidepressant presented as a tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mianserine Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mianserin is used in the management of depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves mood in adult patients.

Mianserin may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Drowsiness - Dry mouth - Constipation - Weight gain - Dizziness

Serious or Rare Side Effects: - Agranulocytosis - Seizures - Cardiac arrhythmias

When prescribing Mianserin, clinicians should consider several safety precautions.

- Monitor blood pressure: watch for orthostatic hypotension, especially at treatment initiation. - Assess for suicidal thoughts: evaluate risk especially in early therapy. - Caution in hepatic impairment: adjust use if liver function is compromised. - Avoid abrupt discontinuation: taper dose to reduce withdrawal symptoms. - Use cautiously in elderly: increased sensitivity to sedative effects. - Store at room temperature: keep in the original container, protect from moisture.

Mianserin can interact with other medicines, requiring attention to potential additive effects.

Major Interactions (Avoid): - MAO inhibitors: concurrent use can cause hypertensive crisis. - SSRIs or other serotonergic agents: risk of serotonin syndrome. - Tramadol: increased risk of seizures and serotonin syndrome. - Linezolid: similar serotonergic risk. - Other tetracyclic antidepressants: additive CNS depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may increase Mianserin plasma levels. - Antihypertensive drugs: additive hypotensive effect. - CNS depressants (e.g., benzodiazepines): enhanced sedation. - Alcohol: may intensify drowsiness. - Anticholinergic medications: increased anticholinergic burden.